Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 30, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2024

Conditions
Malignant GliomaRecurrent Brain NeoplasmRecurrent Childhood Central Nervous System NeoplasmRecurrent Childhood GlioblastomaRecurrent LymphomaRecurrent Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Primary Central Nervous System NeoplasmWHO Grade 3 Glioma
Interventions
OTHER

Pharmacological Study

Correlative studies

DRUG

Selinexor

Given PO

Trial Locations (23)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children's Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT02323880 - Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | Biotech Hunter | Biotech Hunter